PAVmed Provides Business Update and First Quarter 2024 Financial Results

Go back to PAVmed Provides Business Update and First Quarter 2024 Financial Results

Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)

May 14, 2024 8:01 AM EDT

Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD)

The analyst comments "We reiterate our BUY rating on Lucid Diagnostics (LUCD) shares and maintain our price target at $3. Before the market open on... More